2-Bromo-N-(2-cyclohexanecarbonyl-phenyl)-acetamide | 177784-37-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Bromo-N-(2-cyclohexanecarbonyl-phenyl)-acetamide
• 英文别名: N-bromomethylcarbonyl-2-cyclohexylcarbonylaniline；2-bromo-N-[2-(cyclohexanecarbonyl)phenyl]acetamide
• CAS: 177784-37-1
• 化学式: C₁₅H₁₈BrNO₂
• 分子量: 324.217
• InChiKey: HQIHNGQZRFBCHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Bromo-N-(2-cyclohexanecarbonyl-phenyl)-acetamide 在 氨 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 5-Cyclohexyl-1-(4-methoxy-benzyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one
  参考文献：
  名称：

  Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists

  摘要：

  Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the pathophysiology of cardiovascular, cerebrovascular, and renal diseases. Many research groups have embarked on the discovery and development of ET receptor antagonists for the treatment of such diseases. While several compounds, e.g., ambrisentan 2, are in late clinical trials for various indications, one compound (bosentan, Tracleer) is being marketed to treat pulmonary arterial hypertension. Inspired by the structure of ambrisentan 2, we designed a novel class of ET receptor antagonists based on a 1,3,4,5-tetrahydro-1H-benzo[e] [1,4]diazepin-2-one scaffold. Here, we report on the preparation as well as the in vitro and in vivo structure-activity relationships of these derivatives. Potent dual ETA/ETB receptor antagonists with affinities in the low nanomolar range have been identified. In addition, several compounds efficiently reduced arterial blood pressure after oral administration to Dahl salt sensitive rats. In this animal model, the efficacy of the benzo [e] [1,4] diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2.

  DOI：

  10.1021/jm031115r
• 作为产物：
  描述：

  2-氨基苯甲腈 在 水 、 magnesium 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 2-Bromo-N-(2-cyclohexanecarbonyl-phenyl)-acetamide
  参考文献：
  名称：

  Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists

  摘要：

  Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the pathophysiology of cardiovascular, cerebrovascular, and renal diseases. Many research groups have embarked on the discovery and development of ET receptor antagonists for the treatment of such diseases. While several compounds, e.g., ambrisentan 2, are in late clinical trials for various indications, one compound (bosentan, Tracleer) is being marketed to treat pulmonary arterial hypertension. Inspired by the structure of ambrisentan 2, we designed a novel class of ET receptor antagonists based on a 1,3,4,5-tetrahydro-1H-benzo[e] [1,4]diazepin-2-one scaffold. Here, we report on the preparation as well as the in vitro and in vivo structure-activity relationships of these derivatives. Potent dual ETA/ETB receptor antagonists with affinities in the low nanomolar range have been identified. In addition, several compounds efficiently reduced arterial blood pressure after oral administration to Dahl salt sensitive rats. In this animal model, the efficacy of the benzo [e] [1,4] diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2.

  DOI：

  10.1021/jm031115r

文献信息

• Benzodiazepine derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05763437A1

  公开（公告）日：1998-06-09

  Benzodiazepine derivatives of formula (I) wherein R.sup.1 is aryl which may have one or more suitable substituent(s), R.sup.2 is C.sub.3 -C.sub.8 cycloalkyl which may have one or more suitable substituent(s), A is lower alkylene, R.sup.3 is a heterocyclic group selected from the group consisting of tetrahydrofuryl, dioxolanyl, filryl, thienyl, isoxazolyl, pyridyl, benzimidazolyl, benzotiazolyl, benzoxazolyl, benzopyrany, quinolyl, isoquinolyl, tetrahydroisoquinolyl, benzothienyl and benzofuryl, each of which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof, which are useful as a medicament.

  公式（I）中的苯二氮平衍生物，其中R.sup.1是芳基，可以有一个或多个合适的取代基，R.sup.2是C.sub.3-C.sub.8环烷基，可以有一个或多个合适的取代基，A是较低的烷基，R.sup.3是从四氢呋喃基，二氧杂环戊烷基，噻吩基，异恶唑基，吡啶基，苯并咪唑基，苯并噻唑基，苯并噁唑基，苯并吡喃基，喹啉基，异喹啉基，四氢异喹啉基，苯并噻吩基和苯并呋喃基中选择的杂环基，每个基可以有一个或多个合适的取代基，或其药学上可接受的盐，用作药物。
• BENZODIAZEPINE DERIVATIVES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0804425A2

  公开（公告）日：1997-11-05
• US5763437A
  申请人：——

  公开号：US5763437A

  公开（公告）日：1998-06-09
• [EN] BENZODIAZEPINE DERIVATIVES<br/>[FR] DERIVES DE BENZODIAZEPINE
  申请人：——

  公开号：WO1996004254A2

  公开（公告）日：1996-02-15

  [EN] Benzodiazepine derivatives of formula (I) wherein R<1> is aryl which may have one or more suitable substituent(s), R<2> is C3-C8 cycloalkyl which may have one or more suitable substituent(s), A is lower alkylene, R<3> is a heterocyclic group selected from the group consisting of tetrahydrofuryl, dioxolanyl, furyl, thienyl, isoxazolyl, pyridyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzopyranyl, quinolyl, isoquinolyl, tetrahydroisoquinolyl, benzothienyl and benzofuryl, each of which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof, which are useful as a medicament.
  [FR] L'invention se rapporte à des dérivés de benzodiazépine de la formule (I) dans laquelle R<1> représente un aryle pouvant avoir un ou plusieurs substituants appropriés, R<2> représente cycloalkyle en C3-C8 pouvant avoir un ou plusieurs substituants appropriés, A représente alkylène inférieur, R<3> représente un groupe hétérocyclique sélectionné dans le groupe constitué par tétrahydrofuryle, dioxolanyle, furyle, thiényle, isoxazolyle, pyridyle, benzimidazolyle, benzothiazolyle, benzoxazolyle, benzopyranyle, quinolyle, isoquinolyle, tétrahydroisoquinolyle, benzothiényle et benzofuryle, chacun d'eux pouvant avoir un ou plusieurs substituants appropriés, ou à un sel pharmaceutiquement acceptable de ces dérivés, lesquels sont utilisés comme médicaments.
• Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists
  作者：Martin H. Bolli、Judith Marfurt、Corinna Grisostomi、Christoph Boss、Christoph Binkert、Patrick Hess、Alexander Treiber、Eric Thorin、Keith Morrison、Stephan Buchmann、Daniel Bur、Henri Ramuz、Martine Clozel、Walter Fischli、Thomas Weller

  DOI：10.1021/jm031115r

  日期：2004.5.1

  Since its discovery in 1988 by Yanagisawa et al., endothelin (ET), a potent vasoconstrictor, has been widely implicated in the pathophysiology of cardiovascular, cerebrovascular, and renal diseases. Many research groups have embarked on the discovery and development of ET receptor antagonists for the treatment of such diseases. While several compounds, e.g., ambrisentan 2, are in late clinical trials for various indications, one compound (bosentan, Tracleer) is being marketed to treat pulmonary arterial hypertension. Inspired by the structure of ambrisentan 2, we designed a novel class of ET receptor antagonists based on a 1,3,4,5-tetrahydro-1H-benzo[e] [1,4]diazepin-2-one scaffold. Here, we report on the preparation as well as the in vitro and in vivo structure-activity relationships of these derivatives. Potent dual ETA/ETB receptor antagonists with affinities in the low nanomolar range have been identified. In addition, several compounds efficiently reduced arterial blood pressure after oral administration to Dahl salt sensitive rats. In this animal model, the efficacy of the benzo [e] [1,4] diazepin-2-one derivative rac-39au was superior to that of racemic ambrisentan, rac-2.